Horizon Therapeutics Announces Data From TEPEZZA Phase 4 Clinical Trial In Patients With Chronic/Low CAS Thyroid Eye Disease To Be Presented At Endocrine Society Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Horizon Therapeutics announced that data from its TEPEZZA Phase 4 clinical trial in patients with chronic/low CAS thyroid eye disease will be presented at the Endocrine Society Annual Meeting.
June 05, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Horizon Therapeutics' TEPEZZA Phase 4 clinical trial data presentation at the Endocrine Society Annual Meeting may positively impact the company's stock.
The presentation of TEPEZZA Phase 4 clinical trial data at the Endocrine Society Annual Meeting is a significant event for Horizon Therapeutics. Positive results may lead to increased investor confidence and a potential rise in the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100